|
|
Volumn 25, Issue 27, 2007, Pages 4320-4321
|
|
Erlotinib in pancreatic cancer patients: Do we need more information from the NCIC CTG trial? [6]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER GROWTH FACTOR;
EPIDERMAL GROWTH FACTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEMCITABINE;
THROMBIN;
VASCULOTROPIN;
ANTINEOPLASTIC AGENT;
PROTEIN KINASE INHIBITOR;
QUINAZOLINE DERIVATIVE;
VASCULOTROPIN A;
ADVANCED CANCER;
BLOOD CLOTTING;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER SURVIVAL;
CLINICAL TRIAL;
GENE OVEREXPRESSION;
HUMAN;
LETTER;
METASTASIS;
PANCREAS CANCER;
PRIORITY JOURNAL;
PROGNOSIS;
TREATMENT RESPONSE;
TUMOR VASCULARIZATION;
VENOUS THROMBOEMBOLISM;
ANIMAL;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
METABOLISM;
METHODOLOGY;
NOTE;
PANCREAS TUMOR;
PATHOLOGY;
ANIMALS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
HUMANS;
PANCREATIC NEOPLASMS;
PROGNOSIS;
PROTEIN KINASE INHIBITORS;
QUINAZOLINES;
RESEARCH DESIGN;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 34948839916
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2007.12.8801 Document Type: Letter |
|
Times cited : (3)
|
|
References (6)
|
